Volume 94 Issue 30 | p. 17 | Concentrates
Issue Date: July 25, 2016

Juno acquires RedoxTherapies

Department: Business
Keywords: mergers & acquisitions, immuno-oncology, CART, biopharmaceuticals

Juno Therapeutics has acquired RedoxTherapies for $10 million in cash and potential milestone payments. With the deal comes vipadenant, a small-molecule adenosine A2A receptor antagonist that has the potential to inhibit immunosuppressive pathways in cancer. Juno intends to test the molecule in combination with its engineered T-cell candidates. Only a few days before announcing the acquisition, Juno was allowed to restart a Phase II leukemia clinical trial of its lead product candidate, JCAR015. FDA had halted the trial when two patients died after the addition of another drug to the treatment regimen.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment